Detailed Abstract
[BP Oral Presentation 1 - Biliary & Pancreas (Biliary Disease/Surgery)]
[BP OP 1-S2] Clinicopathological Feature And Impact of Adjuvant Therapy in T1 Pancreatic Ductal Adenocarcinoma: a Single Institutional Retrospective Analysisture
Soo Yeun LIM 1, Sujin PARK 1, HyeJeong JEONG 1, Hochang CHAE 1, Hyeong Seok KIM 1, So Jeong YOON 1, Hongbeom KIM 1, In Woong HAN 1, Jin Seok HEO 1, Sang Hyun SHIN 1
1 Division of Hepatobiliary-Pancreatic Surgery, Department of Surgery, Samsung Medical Center, REPUBLIC OF KOREA
Background : Despite the recognized impact of tumor size on patient survival in pancreatic ductal adenocarcinoma (PDAC), specifically represented by its T stage, the investigation into T1 PDAC itself has been limited due to its rarity. This study aimed to investigate the clinicopathological characteristics and prognostic factors of T1 PDAC.
Methods : Medical records of consecutive 293 patients who underwent surgical resection for T1 PDAC from 2000 to 2020 were retrospectively reviewed. The clinicopathological characteristics were examined, and risk factors associated with survival were identified.
Results : The 5-year overall survival (OS) and disease-free survival (DFS) were 38.8%, and 33.5%, respectively. The tumor size was not associated with patient survival within T1 stage (p = 0.500). Positive lymph node (N+) showed a poorer OS and DFS compared to negative lymph node (N-) (p = 0.006 and <0.001, respectively). When compared survival between subgroups divided based on N stage and adjuvant therapy, patients who underwent adjuvant therapy showed better prognosis in both N+ and N- groups. N- group with adjuvant therapy showed the best OS and DFS, and N+ group with adjuvant therapy showed similar survival curve compared to N- group without adjuvant therapy (p=0.360 in OS, and p=0.433 in DFS). In multivariable analysis, age, BMI, lymphovascular invasion, perineural invasion, operative time, and adjuvant therapy were identified as independent risk factors.
Conclusions : This study emphasizes the importance of adjuvant therapy in T1 PDAC. Adjuvant therapy enhances patient survival of T1 PDAC in both N+ and N- groups, especially in T1N0 patients.
Methods : Medical records of consecutive 293 patients who underwent surgical resection for T1 PDAC from 2000 to 2020 were retrospectively reviewed. The clinicopathological characteristics were examined, and risk factors associated with survival were identified.
Results : The 5-year overall survival (OS) and disease-free survival (DFS) were 38.8%, and 33.5%, respectively. The tumor size was not associated with patient survival within T1 stage (p = 0.500). Positive lymph node (N+) showed a poorer OS and DFS compared to negative lymph node (N-) (p = 0.006 and <0.001, respectively). When compared survival between subgroups divided based on N stage and adjuvant therapy, patients who underwent adjuvant therapy showed better prognosis in both N+ and N- groups. N- group with adjuvant therapy showed the best OS and DFS, and N+ group with adjuvant therapy showed similar survival curve compared to N- group without adjuvant therapy (p=0.360 in OS, and p=0.433 in DFS). In multivariable analysis, age, BMI, lymphovascular invasion, perineural invasion, operative time, and adjuvant therapy were identified as independent risk factors.
Conclusions : This study emphasizes the importance of adjuvant therapy in T1 PDAC. Adjuvant therapy enhances patient survival of T1 PDAC in both N+ and N- groups, especially in T1N0 patients.
SESSION
BP Oral Presentation 1
Room B 3/21/2024 3:30 PM - 4:30 PM